LifeSci Communications Fierce Pharma Asia—Takeda's Anima mRNA translation pact, China digital health incubator; Daiichi's COVID-19 vaccine
Por um escritor misterioso
Descrição
Takeda penned a potentially billion-dollar deal with Anima Biotech to work on mRNA translation modulators for neurological diseases. The Japanese pharma als
Anima Biotech - mRNA Lightning Platform
JCI - Article_in_issue
Press Releases - Media - Daiichi Sankyo
Anima Biotech - Company info. interviews, news
Sponsor Detail Template – Chinese American Biopharmaceutical Society
PharmaCompass – Grow Your Pharma Business Digitally
Sponsor Detail Template – Chinese American Biopharmaceutical Society
Japan's Daiichi Sankyo to seek OK for omicron booster by April 2024 - Nikkei Asia
LifeSci Communications Fierce Pharma Asia—Takeda's Anima mRNA translation pact, China digital health incubator; Daiichi's COVID-19 vaccine
Daiichi Sankyo to establish Japan's first mRNA production facility
Japan panel endorses first domestically developed COVID vaccine - The Japan Times
China Accelerating Development of its First Homegrown mRNA Covid Vaccine - Bloomberg
de
por adulto (o preço varia de acordo com o tamanho do grupo)
